Pacer WealthShield ETF (PWS)
| Assets | $14.56M |
| Expense Ratio | 0.60% |
| PE Ratio | 28.82 |
| Forward PE | 21.44 |
| Shares Out | 450,000 |
| Dividend | $0.68 (2.12%) |
| Ex-Dividend Date | Sep 3, 2026 |
| Payout Frequency | Quarterly |
| Payout Ratio | 61.06% |
| Volume | 2,216 |
| Open | 31.94 |
| Previous Close | 31.86 |
| Day's Range | 31.94 - 32.12 |
| 52-Week Low | 31.18 |
| 52-Week High | 33.83 |
| Beta | 0.41 |
| Holdings | 320 |
| Inception Date | Dec 11, 2017 |
About PWS
Fund Home PageThe Pacer WealthShield ETF (PWS) is an exchange-traded fund that is based on the Pacer Wealth Shield Total Return index. The fund tracks an index that toggles between equity and Treasurys, or a combination of both, on a monthly basis depending on monthly moving averages. PWS was launched on Dec 11, 2017 and is issued by Pacer.
Top 10 Holdings
42.17% of assets| Name | Symbol | Weight |
|---|---|---|
| United States Treasury Bills 0% | B.0 12.31.26 | 17.04% |
| NVIDIA Corporation | NVDA | 4.23% |
| Apple Inc. | AAPL | 3.81% |
| Microsoft Corporation | MSFT | 3.09% |
| Eli Lilly and Company | LLY | 3.01% |
| U.S. Bank Money Market Deposit Account | n/a | 2.39% |
| Meta Platforms, Inc. | META | 2.38% |
| Cisco Systems, Inc. | CSCO | 2.21% |
| Amazon.com, Inc. | AMZN | 2.08% |
| Johnson & Johnson | JNJ | 1.93% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Sep 3, 2026 | $0.33672 | Sep 8, 2026 |
| Jun 4, 2026 | $0.0682 | Jun 8, 2026 |
| Mar 5, 2026 | $0.01636 | Mar 9, 2026 |
| Dec 30, 2025 | $0.25922 | Jan 5, 2026 |
| Sep 4, 2025 | $0.07966 | Sep 10, 2025 |
| Jun 5, 2025 | $0.11621 | Jun 11, 2025 |
Performance
PWS had a total return of 1.76% in the past year, including dividends. Since the fund's inception, the average annual return has been 4.29%.
News
ConSynance Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of CSTI-500 for Prader-Willi Syndrome
RENSSELAER, N.Y., June 16, 2026 (GLOBE NEWSWIRE) -- ConSynance Therapeutics, Inc. (“ConSynance”), a clinical-stage biotechnology company developing first-in-class therapies for neurobehavioral symptom...
Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period
Participants who resumed VYKAT XR following a 16-week randomized withdrawal period demonstrated improvements in hyperphagia and behavioral symptoms as early as Week 13, with benefits continuing throug...
Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026
-- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in ...
Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome
BOSTON, June 12, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rar...
Saniona Receives Positive Feedback from FDA on Regulatory Path for Tesomet in Prader-Willi Syndrome (PWS)
PRESS RELEASE